Compare CCNE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | DRTS |
|---|---|---|
| Founded | 1865 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.3M | 607.1M |
| IPO Year | N/A | N/A |
| Metric | CCNE | DRTS |
|---|---|---|
| Price | $28.04 | $7.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $32.00 | $9.50 |
| AVG Volume (30 Days) | 141.2K | ★ 310.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.21 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $11.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.32 | $2.30 |
| 52 Week High | $30.84 | $8.60 |
| Indicator | CCNE | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 56.92 |
| Support Level | $25.66 | $6.57 |
| Resistance Level | $28.32 | $7.77 |
| Average True Range (ATR) | 0.92 | 0.49 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 6.02 | 50.29 |
CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.